Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer

Feng Xu,Beizheng Xu,Jiang Wang,Haiyan Liu,Aibing Deng,Xuanmei Li,Jian Song,Jianjun Mao

doi:10.1186/s12885-020-07444-6

Feng Xu, Beizheng Xu + Show 6 more

Open Access

https://doi.org/10.1186/s12885-020-07444-6

Copy DOI

Abstract

BackgroundThis study is designed to investigate the clinical value of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer.MethodsA total of 412 lung cancer patients admitted to Cangzhou People’s Hospital from March 2018 to March 2020 were collected and divided into test group and control group based on their treatment schedules. The test group received systemic chemotherapy combined with bronchoscopic interventional cryotherapy, while the control group received systemic chemotherapy alone. Tumor objective response rate (ORR), disease control rate (DCR), serum tumor marker levels, serum matrix metalloproteinase (MMP) content, T cell subset level, survival time and adverse reactions of the two groups were observed.ResultsThe ORR and DCR of the test group were better than those of the control group, while those of the non-small cell lung cancer (NSCLC) patients in the test group were better than patients with small-cell lung cancer (SCLC) (P < 0.05). There was no significant difference in serum tumor marker levels, MMP content and T cell subset level between the two groups before treatment. After treatment, the serum tumor marker levels along with serum MMP-2, MMP-9 and CD8+ levels in the test group decreased more remarkably, while CD4+ and CD4+/CD8+ levels increased more significantly than those in the control group (P < 0.05). The serum MMP-2 and MMP-9 of NSCLC patients in the test group decreased more remarkably than those of SCLC patients, while there was no significant difference in CD8+, CD4+ and CD4+/CD8+. The progression-free survival and overall survival of the test group were obviously longer than those of the control group. The same trend was observed in NSCLC patients compared with SCLC patients in the test group (P < 0.05).ConclusionsSystemic chemotherapy combined with bronchoscopic interventional cryotherapy for lung cancer has good clinical efficacy and safety, and can be widely used in clinical practice.

Highlights

This study is designed to investigate the clinical value of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer
The curative effect of systemic chemotherapy combined with bronchoscopic interventional cryotherapy is superior than systemic chemotherapy alone; 2
Systemic chemotherapy combined with bronchoscopic interventional cryotherapy can significantly prolong the survival time of patients; 3

Summary

Introduction

This study is designed to investigate the clinical value of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer. Lung cancer is a prevalent malignant tumor in clinical practice with high and annually increasing morbidity and mortality worldwide [1, 2]. Lung cancer is easy to be neglected due to a lack of obvious symptoms in the early stage. The disease has developed to the middle and advanced stage when patients appear obvious discomfort, which makes patients miss the opportunity of surgery. Systemic chemotherapy is the main treatment for patients with advanced lung cancer, which can effectively kill tumor cells to prolong the survival time of patients, but there are many side effects and patients will suffer greatly. It is crucial to optimize the treatment for lung cancer patients

Objectives

Methods

Results

Discussion

Conclusion